Question 1

What is a RAS mutation?

Accepted Answer

A RAS mutation is a genetic fault that causes cells to keep growing when they should stop — which is, in essence, how cancer forms. RAS mutations appear in roughly a quarter of all human cancers and are especially common in some of the hardest-to-treat forms, including pancreatic cancer. For decades, scientists labelled the RAS protein 'undruggable' because its biological structure made it nearly impossible to block with existing drug design techniques.

Question 2

What is precision oncology?

Accepted Answer

Precision oncology is an approach to cancer treatment that targets the specific genetic mutations driving a tumour, rather than using broad treatments like chemotherapy that affect all cells. Instead of a one-size-fits-all approach, precision oncology seeks to match the right therapy to the right mutation. It has already produced some of the most commercially successful drugs in modern pharmaceuticals, and RAS inhibitors represent one of the most ambitious frontiers within this field.

Question 3

What is a RAS inhibitor?

Accepted Answer

A RAS inhibitor is a drug designed to block the faulty signals produced by mutated RAS proteins, effectively telling cancer cells to stop growing. Developing these inhibitors has been one of oncology's greatest scientific challenges for decades. Recent breakthroughs in understanding the RAS protein's structure have made it possible to design molecules that can target it, and a small group of clinical-stage biotech companies are now testing these drugs in advanced trials.

Question 4

What is a Phase 3 clinical trial?

Accepted Answer

A Phase 3 trial is the final stage of clinical testing before a drug company can apply for regulatory approval to bring a treatment to market. It involves large patient groups and is designed to confirm that a drug is both effective and safe. A positive Phase 3 result is a major commercial milestone — but Phase 3 trials can and do fail, which is why clinical-stage biotech stocks carry significant share price risk in both directions.

Question 5

Is RAS inhibitor investing risky?

Accepted Answer

Yes — this is a high-risk investment theme. All three lead companies (RVMD, ERAS, and CRDF) are clinical-stage, meaning they are largely pre-revenue and their valuations depend almost entirely on future trial results and regulatory approvals. If trial results disappoint, share prices can fall sharply and quickly. Investors should treat this as a long-term, higher-risk allocation and never invest more than they can afford to lose.

Question 6

Top RAS inhibitor stocks to watch in 2026?

Accepted Answer

The three companies featured in this precision oncology theme are Revolution Medicines (RVMD), Erasca (ERAS), and Cardiff Oncology (CRDF). RVMD is the largest by market cap at approximately $19.1 billion and is running a Phase 3 trial for daraxonrasib in pancreatic cancer. ERAS focuses on blocking the RAS/MAPK pathway at multiple points, while CRDF is a smaller, higher-risk company targeting metastatic pancreatic ductal adenocarcinoma and other RAS-mutated tumours.

Question 7

How does market cap affect a RAS inhibitor basket?

Accepted Answer

Because Revolution Medicines (RVMD) accounts for the vast majority of this basket's total market capitalisation, the day-to-day performance of the group is heavily driven by what happens to RVMD specifically. Investors attracted by the stories of smaller companies like ERAS or CRDF should understand that the basket's overall returns may not fully reflect those individual names. It effectively behaves like a large-cap anchor with smaller, higher-risk companies orbiting around it.

Question 8

Should I add precision oncology stocks to my portfolio?

Accepted Answer

Precision oncology, and RAS inhibitors in particular, represent a genuine long-term growth opportunity — but one that comes with meaningful risk. Clinical-stage biotech can deliver sharp gains on positive trial results, but setbacks can be equally severe. This theme is best suited to investors who understand the binary nature of clinical trial outcomes, are comfortable with volatility, and are looking for a higher-risk satellite allocation rather than a core portfolio holding.

Question 9

Why is pancreatic cancer so hard to treat?

Accepted Answer

Pancreatic cancer is one of the most aggressive and difficult-to-treat cancers in existence, in part because RAS mutations are particularly prevalent in it. Until recently, patients had few targeted treatment options and relied primarily on chemotherapy. The development of RAS inhibitors like Revolution Medicines' daraxonrasib represents a potential step-change in how this disease could be managed, which is why clinical results from this field are watched so closely by both the medical and investment communities.

Question 10

Why are RAS inhibitor stocks getting attention now?

Accepted Answer

Two key factors have brought this theme into focus. First, scientific breakthroughs have finally made it possible to design drugs that target the previously 'undruggable' RAS protein. Second, former Senator Ben Sasse publicly highlighted Revolution Medicines' Phase 3 trial for a pancreatic cancer pill, signalling that the story has moved well beyond specialist oncology circles. These two forces together — scientific momentum and rising public awareness — are drawing serious investor attention to the sector.

Question 11

What is the growth potential of the RAS inhibitor market?

Accepted Answer

The potential is significant. RAS mutations appear in roughly a quarter of all human cancers, representing an enormous unmet medical need. Targeted therapies that successfully crack RAS could follow the path of earlier precision oncology breakthroughs, which generated billions in revenue and genuinely extended patients' lives. The companies in this group are pursuing some of the most technically ambitious oncology programmes in the industry — and that ambition is precisely what makes both the opportunity and the risk so large.

Question 12

How can I invest in precision oncology RAS inhibitor stocks through Nemo?

Accepted Answer

Nemo is an ADGM-regulated platform that offers commission-free investing in US stocks, including the companies in this RAS inhibitor theme. Fractional shares mean you can start investing in this theme from as little as $1, making it accessible for investors in Africa and beyond who want exposure without needing significant upfront capital. Nemo also provides AI-powered research tools and detailed data on each company in the basket to help you make informed decisions.

The Cancer Mutation That Scientists Finally Cracked

The Cancer Mutation That Scientists Finally Cracked

The 19 Billion Gamble on Undruggable Tumours

Why Chasing the Undruggable Cancer Mutation Could Be Worth the Risk

When Politicians Notice Pills

The 19 Billion Gamble on Undruggable Tumours

Why Chasing the Undruggable Cancer Mutation Could Be Worth the Risk

When Politicians Notice Pills

The Satellites Orbiting the Giant

The Reality of Clinical Roulette

Deep Dive

Market & Opportunity

Key Companies

Primary Risk Factors

Growth Catalysts

이 기회에 투자하는 방법

자주 묻는 질문

최신 인사이트

Why ASML's Bulging Backlog Is a Chip Supercycle Tell

Waymo Crosses The Border Into Driverless Territory

Why a $6.3bn Deal Just Reshaped Data Security

Why Boeing's Delivery Logjam Could Finally Break

Neutron's Slip to 2027 Puts Rocket Lab's Growth Story to the Test

최신 인사이트

Why ASML's Bulging Backlog Is a Chip Supercycle Tell

Waymo Crosses The Border Into Driverless Territory

Why a $6.3bn Deal Just Reshaped Data Security

Why Boeing's Delivery Logjam Could Finally Break

Neutron's Slip to 2027 Puts Rocket Lab's Growth Story to the Test

Why ASML's Bulging Backlog Is a Chip Supercycle Tell

Waymo Crosses The Border Into Driverless Territory

Why a $6.3bn Deal Just Reshaped Data Security

Why Boeing's Delivery Logjam Could Finally Break

Neutron's Slip to 2027 Puts Rocket Lab's Growth Story to the Test

Why ASML's Bulging Backlog Is a Chip Supercycle Tell

Waymo Crosses The Border Into Driverless Territory

Why a $6.3bn Deal Just Reshaped Data Security

Why Boeing's Delivery Logjam Could Finally Break

Neutron's Slip to 2027 Puts Rocket Lab's Growth Story to the Test